尿路性器癌に対するCDDP単独あるいは多剤併用療法

Abstract

Twenty-four patients with advanced genitourinary cancer were treated with cis-diamminedichloroplatinum (II ) (CDDP) alone or three combination regimens. Three regimens were used: CBV regimen; CDDP, bleomycin (BLM) and vincristine (VCR), ACE regimen; adriamycin(ADM), CDDP and cyclophosphamide (EDX), CMF regimen; CDDP, mytomycin C (MMC) and 5-Fu. In treatment with CDDP alone, one patient with testicular tumor achieved complete response, and in three no change including one rena! cell carcinoma and two prostatic carcinomas and in a patient with bladder tumor, progressive disease were noted. In the combination regimens with CDDP and other agents, four of seven patients with testicular tumor achieved complete response and three patients showed partial response. Among six patients with renal cell carcinoma except 1 no evaluable case, one patient achieved complete response, and three no change and one progressive disease were noted. In two of three showing no change was observed significant subjective improvement. Four of five patients with urothelioma obtained partial response and the other showed progressive disease. A case of prostatic carcinoma was no change and a case of penile cancer showed partial response. Gastrointestinal toxicity occurred in all patients. Leucopenia less than 2, 000/mm3 was seen in 4 patients (17%) and renal dysfunction in 4 (17%). These side effects were transient except 1 patient.